In Brief: LocalMed
This article was originally published in The Gray Sheet
LocalMed: Files investigational device exemption with FDA for its PerfusaSleeve device "which converts an ordinary angioplasty catheter into a perfusion balloon," the company says in a Feb. 8 release. Using the over-the-balloon technology employed in LocalMed's InfusaSleeve drug delivery catheter, cleared via 510(k) in October 1994 ("The Gray Sheet" Oct. 31, 1994, p. 3), PerfusaSleeve "aligns with the balloon and permits blood to flow during angioplasty procedures by routing it around the angioplasty balloon." The blood enters "perfusion channels upstream from the balloon and exits through ports distal to the balloon," LocalMed explains...
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.